Xconomy: T2 Biosystems, On-Q-ity, and GnuBIO Report Progress in Hunting for Signs of Disease

▤ Summary

And the Lexington, MA-based firm is revealing results this morning from lab experiments that show the potential of its diagnostic for Candida infections to improve upon the current culture-based methods of spotting the fungal invaders.Shortening the time needed to diagnose patients’ specific yeast infections enables doctors to put them on the proper antifungal treatment quickly, potentially saving their lives, John McDonough, T2 Biosystems’ CEO, said.McDonough says that the company is also pursuing other tests for use with its system, including one for bacterial infections, but he declined to provide specifics about the type of bugs or timing of the commercial release.The company, a spinout of Harvard physics professor David Weitz’s lab, revealed sequencing data involving cancer-related genes generated by a prototype system.“Based on the quality of the data being generated by the GnuBIO platform, I’m very excited about its potential for gene-expression assays for applications, ranging from small-molecule profiling to analyses in oncology,” Justin Lamb, senior scientist at the Broad Institute, said in a statement.

▦ Linked Companies

Shareaholic

$1M to $5M